We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: December 28, 2010
Last Update Posted: May 15, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Daniel Riche, University of Mississippi Medical Center
Results First Submitted: March 19, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Hyperlipidemia
Blood Pressure
Oxidative Stress
Interventions: Drug: Pterostilbene 50 mg twice daily
Drug: Placebo
Drug: Grape Extract
Drug: Pterostilbene 125 mg twice daily

  Participant Flow

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
High Dose Pterostilbene 125 mg twice daily
Low Dose Pterostilbene 50 mg twice daily
Low Dose Combination Pterostilbene 50 mg/Grape Extract 100 mg twice daily
Placebo Matching placebo twice daily
Total Total of all reporting groups

Baseline Measures
   High Dose   Low Dose   Low Dose Combination   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 20   20   20   20   80 
[Units: Participants]
<=18 years   0   0   0   0   0 
Between 18 and 65 years   16   19   17   17   69 
>=65 years   4   1   3   3   11 
[Units: Years]
Mean (Standard Deviation)
 53.6  (11.2)   53.6  (7.9)   53.0  (13.7)   54.4  (11.9)   53.6  (11.2) 
[Units: Participants]
Female   14   15   15   13   57 
Male   6   5   5   7   23 
Region of Enrollment 
[Units: Participants]
United States   20   20   20   20   80 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Triglycerides   [ Time Frame: Baseline and 6-8 weeks ]

2.  Secondary:   Subjective Adverse Effects   [ Time Frame: Baseline and 6-8 weeks ]

3.  Secondary:   Blood Pressure   [ Time Frame: 6-8 weeks ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information